Experimental therapy works better if taken earlier in Alzheimer’s
An experimental oral therapy called blarcamesine appears to slow the progression of Alzheimer’s disease, reducing the rate of cognitive decline and preserving daily function over the long term, according to new trial data from its developer, Anavex Life Sciences. The data “indicate disease-modifying effect of oral blarcamesine and…